Abstract
With a lifetime prevalence of more than 16% worldwide, major depressive disorder is one of the most common psychiatric disorders. Only one third of patients experience a complete therapeutic improvement with the use of current antidepressant drugs, with a therapeutic effect appearing only after several weeks of treatment. Hence, a better understanding of the mechanisms of action of current antidepressant treatments is needed to ultimately identify new targets and enhance beneficial effects. Given the intimate relationships between astrocytes and neurons at synapses and the ability of astrocytes to “sense” neuronal communication and release gliotransmitters, an attractive hypothesis is emerging stating that the effects of antidepressants on brain function could be, at least in part, mediated by direct influences of astrocytes on neuronal networks. This review aims at highlighting the involvement of astrocytes and gliotransmission in the antidepressant effects of both non- and pharmacological therapies.
Keywords: Antidepressants, astrocytes, DBS, gliotransmission, tripartite synapse.
Current Drug Targets
Title:Astrocytes and Gliotransmitters: New Players in the Treatment of Major Depression?
Volume: 14 Issue: 11
Author(s): Adeline Etiévant, Laura Lambás-Señas, Hélène Scarna, Guillaume Lucas and Nasser Haddjeri
Affiliation:
Keywords: Antidepressants, astrocytes, DBS, gliotransmission, tripartite synapse.
Abstract: With a lifetime prevalence of more than 16% worldwide, major depressive disorder is one of the most common psychiatric disorders. Only one third of patients experience a complete therapeutic improvement with the use of current antidepressant drugs, with a therapeutic effect appearing only after several weeks of treatment. Hence, a better understanding of the mechanisms of action of current antidepressant treatments is needed to ultimately identify new targets and enhance beneficial effects. Given the intimate relationships between astrocytes and neurons at synapses and the ability of astrocytes to “sense” neuronal communication and release gliotransmitters, an attractive hypothesis is emerging stating that the effects of antidepressants on brain function could be, at least in part, mediated by direct influences of astrocytes on neuronal networks. This review aims at highlighting the involvement of astrocytes and gliotransmission in the antidepressant effects of both non- and pharmacological therapies.
Export Options
About this article
Cite this article as:
Etiévant Adeline, Lambás-Señas Laura, Scarna Hélène, Lucas Guillaume and Haddjeri Nasser, Astrocytes and Gliotransmitters: New Players in the Treatment of Major Depression?, Current Drug Targets 2013; 14 (11) . https://dx.doi.org/10.2174/13894501113149990197
DOI https://dx.doi.org/10.2174/13894501113149990197 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews An Overview of Acute Flaccid Myelitis
CNS & Neurological Disorders - Drug Targets Tryptamine Induces Axonopathy and Mitochondriopathy Mimicking Neurodegenerative Diseases via Tryptophanyl-tRNA Deficiency
Current Alzheimer Research Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View
Current Neuropharmacology D1 and Functionally Selective Dopamine Agonists as Neuroprotective Agents in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Therapeutic Use of Snake Venom Components: A Voyage from Ancient to Modern India
Mini-Reviews in Organic Chemistry The Role of ER Stress-Induced Apoptosis in Neurodegeneration
Current Alzheimer Research Potential Application of Induced Pluripotent Stem Cells in Cell Replacement Therapy for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets A Current Review of Cypermethrin-Induced Neurotoxicity and Nigrostriatal Dopaminergic Neurodegeneration
Current Neuropharmacology Green Tea, A Medicinal Food with Promising Neurological Benefits
Current Neuropharmacology alpha Conotoxins Nicotinic Acetylcholine Receptor Antagonists as Pharmacological Tools and Potential Drug Leads
Current Medicinal Chemistry Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Current Pharmaceutical Design New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Pathogenic Mechanisms and Therapeutic Strategies in Spinobulbar Muscular Atrophy
CNS & Neurological Disorders - Drug Targets Nebivolol: More Than a Highly Selective Beta Blocker
Recent Patents on Cardiovascular Drug Discovery Cannabinoid Signaling in Glial Cells in Health and Disease
Current Neuropharmacology Novel Antiviral Strategies to Combat Human Arenavirus Infections
Current Molecular Medicine Metabolic Dysfunction in Alzheimers Disease and Related Neurodegenerative Disorders
Current Alzheimer Research